{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/hyperthyroidism/","result":{"data":{"firstChapter":{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field bc011fac-01eb-4ff5-af52-dfeba1dade5a --><h1>Hyperthyroidism: Summary</h1><!-- end field bc011fac-01eb-4ff5-af52-dfeba1dade5a -->","htmlStringContent":"<!-- begin item cd2365d3-dcb8-492b-a199-823df39fabad --><!-- begin field 628fbe7c-8211-4e03-9a54-6b2fe4153122 --><ul><li>Hyperthyroidism is a biochemical diagnosis when there is pathologically increased thyroid hormone production and secretion by the thyroid gland.<ul><li>Thyrotoxicosis is the clinical manifestation of excess circulating thyroid hormones due to any cause, including hyperthyroidism.</li></ul></li><li>Primary hyperthyroidism occurs when thyrotoxicosis is caused by an abnormality of the thyroid gland, such as Graves' disease or a nodular goitre.<ul><li>Overt primary hyperthyroidism is when thyroid-stimulating hormone (TSH) is suppressed below the normal reference range, and free thyroxine (FT4) and/or free triiodothyronine (FT3) concentrations are above the normal reference range.</li><li>Subclinical hyperthyroidism is diagnosed when TSH is suppressed below the normal reference range, but FT4 and FT3 concentrations are within the normal reference range.</li></ul></li><li>Thyrotoxicosis without hyperthyroidism describes thyrotoxicosis without thyroid gland overactivity, which is usually transient due to thyroiditis or excess levothyroxine intake.</li><li>Complications of hyperthyroidism include thyrotoxic crisis, Graves' orbitopathy, compression symptoms from a large goitre, atrial fibrillation, and heart failure.</li><li>A diagnosis of hyperthyroidism should be suspected if there are:<ul><li>Symptoms such as anxiety, palpitations, tremor, weight loss, diarrhoea, and heat intolerance.</li><li>Signs such as agitation, sinus tachycardia, a goitre and/or thyroid nodules.</li><li>Features of Graves' orbitopathy, such as excessive eye watering, double vision, change in visual acuity or colour vision, eyelid retraction or lid lag, proptosis.</li></ul></li><li>Assessment of a person with suspected hyperthyroidism includes:<ul><li>Asking about typical symptoms, recent non-thyroidal illness, drug treatments, and risk factors for thyroid disease.</li><li>Examining for typical signs, a goitre or thyroid swelling, and signs of Graves' orbitopathy.</li><li>Checking serum TSH level initially, and measuring FT4 and FT3 in the same sample if the TSH level is suppressed.</li><li>Rechecking thyroid function tests (TFTs) 3 months after the initial result to exclude other causes of a transiently suppressed TSH, if subclinical hyperthyroidism is suspected.</li><li>Considering checking additional bloods such as inflammatory markers and thyroid autoantibodies, if clinically indicated.</li></ul></li><li>Management of a person with hyperthyroidism includes:<ul><li>Arranging emergency admission if a serious complication is suspected.</li><li>Arranging urgent endocrinology referral if a pituitary or hypothalamic disorder is suspected.</li><li>Arranging endocrinology referral or advice for all other people with new-onset overt hyperthyroidism.</li><li>Arranging endocrinology referral for persistent subclinical hyperthyroidism, if TSH levels are lower than 0.1 mU/L at least 3 months apart and there is evidence of thyroid disease.</li><li>Considering beta-blocker treatment for adrenergic symptoms.</li><li>Considering seeking specialist advice about starting antithyroid drugs, if clinically indicated.</li><li>Offering advice on sources of information and support.</li><li>Ensuring people on antithyroid drugs or other treatments follow specialist advice regarding adverse effects and regular blood monitoring.</li></ul></li><li>Management of women of childbearing potential includes:<ul><li>Arranging referral for pre-pregnancy counselling for all women with overt or subclinical hyperthyroidism who are planning a pregnancy.</li><li>Advising the woman to seek immediate medical advice if pregnancy is suspected or confirmed. </li><li>Arranging urgent specialist referral for all pregnant women with current or previous overt or subclinical hyperthyroidism.</li><li>Checking TFTs postpartum, depending on specialist advice.</li></ul></li></ul><!-- end field 628fbe7c-8211-4e03-9a54-6b2fe4153122 --><!-- end item cd2365d3-dcb8-492b-a199-823df39fabad -->","topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","aliases":[],"chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","slug":"management","fullItemName":"Management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753","topicId":"4369594d-9952-48d2-89e3-17e591c8762d","topicName":"Hyperthyroidism","slug":"hyperthyroidism","aliases":[],"topicSummary":"Hyperthyroidism occurs when an excess of circulating thyroid hormones (thyrotoxicosis) is produced by an overactive thyroid gland.","lastRevised":"Last revised in January 2021","nextPlannedReviewBy":"2025-02-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2025-02","nextPlannedReviewByDisplay":"February 2025","specialities":[{"id":"aa304738-44fc-5b1d-af3b-42cce5d27663","name":"Endocrine and metabolic","slug":"endocrine-metabolic"}],"chapters":[{"id":"59f9bdf8-6311-583d-9fe9-52c678d352db","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"146e5bec-d1eb-5ba0-9e81-f3816c76c97a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"129b45b2-8296-54fd-9b82-246f53a0c38a","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"94bb9adc-590a-5092-a39d-eafdcb359b5b","slug":"changes","fullItemName":"Changes"},{"id":"0587f71f-c66c-57d3-82dc-d217875883ba","slug":"update","fullItemName":"Update"}]},{"id":"1056d2a8-5a53-5386-8dab-1f19fc4a963f","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"d5707303-4d8e-53dd-9591-510f1f75ea88","slug":"goals","fullItemName":"Goals"},{"id":"c725a50c-0e88-5dca-a743-83b0aec2cf6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"423f188d-b3d1-599b-b36e-d8986253ac12","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"a7f71a23-ba29-5115-a37a-e10730ecfebe","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3769fad6-d54a-5b84-9378-d5fed321c43f","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f546d633-22ad-5b3a-addf-c14ed5a316e4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a47d1c6f-bb45-556c-9f6f-1be5eb0fee97","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"87205244-f824-5403-8c75-27a9396c3d3c","slug":"definition","fullItemName":"Definition"},{"id":"297effea-8b73-56d9-b953-894efa713b64","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6c2d617f-c4bf-53cd-ad15-3c4e50b4f917","slug":"causes","fullItemName":"Causes"},{"id":"a8477f19-2c3c-55eb-9cf0-52683adbf104","slug":"prevalence","fullItemName":"Prevalence"},{"id":"5d8a6eb0-ae1c-5dc0-976b-c6dc76c822d0","slug":"complications","fullItemName":"Complications"},{"id":"606c2ced-041a-59db-84ad-9bdbc9d30b29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"25bebca1-01a3-571a-bc2f-de52655661fd","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"535b7a8d-3411-51df-831d-85332e2925e0","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"3e2f3be8-a4e7-55cc-a90e-fc9bc179ce65","slug":"assessment","fullItemName":"Assessment"}]},{"id":"c4bec08d-e5b3-509c-bea9-a31e8270f443","slug":"management","fullItemName":"Management","subChapters":[{"id":"4b553103-7c9a-5df2-a66d-ca71eb230d75","slug":"management","fullItemName":"Scenario: Management"},{"id":"f01fb4b1-5479-506a-aab6-3d89022ca8d1","slug":"pre-conception-pregnancy-postpartum","fullItemName":"Scenario: Pre-conception, pregnancy, and postpartum"}]},{"id":"410c1a25-4e25-5a82-9e68-74da126c2a52","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"8a4baacf-8743-54dd-b0d2-6f9c63faed0f","slug":"propylthiouracil","fullItemName":"Propylthiouracil"},{"id":"5fecf90d-1aa4-5bb3-9e03-3603d3bff170","slug":"carbimazole","fullItemName":"Carbimazole"},{"id":"9f0433e8-fb86-5755-b708-070c08e61a4e","slug":"beta-blockers","fullItemName":"Beta-blockers"}]},{"id":"d5890c99-4277-5691-82b8-db4d899a0577","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"02257fcd-f37e-5344-be29-947639722e86","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"ad43c9e6-b7b5-5112-a0c3-cceb0846f218","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"19745d5f-1ede-5a4c-bc7f-14ffd9dcb077","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"28c4e1a4-4c14-58af-a7eb-7064465157f4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"afef01bd-ae56-54fa-96f9-395242020ab0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1fc2600e-afe1-582b-b40e-ba61a21de9f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"b29c805a-fe2a-529d-a4e8-e0a837f7663c","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"c3c8bd52-950a-5ac1-a8f6-31ee314de753"}},"staticQueryHashes":["3666801979"]}